Clinical Trials Browser

NIH × Insulin-Like Growth Factor I, Resistance To × cixutumumab × Clear all

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms